Dmytro Kharkov

MeiraGTx platform boosts gene therapy efficiency with AI-driven promoter activity

MeiraGTx platform boosts gene therapy efficiency with AI-driven promoter activity
@MeiraGTx: MeiraGTx boosts gene therapy

At the American Society of Human Genetics 2025 conference, MeiraGTx showcased its AI-driven platform that can significantly enhance the efficiency of gene therapies. This cutting-edge technology is capable of boosting synthetic promoter activity by up to six times and increasing protein expression by up to 20 percent.

These advancements promise to improve the effectiveness and safety of gene therapies by creating more potent delivery vectors. The announcement underscores the vital role of artificial intelligence in propelling the field of genomics and synthetic biology forward. As the industry looks towards improved gene delivery methods, MeiraGTx is positioned at the forefront of this innovation.

The momentum generated by MeiraGTx’s AI-powered platform builds upon the company’s recent progress in the field, including landmark developments such as its gene therapy for Parkinson’s disease gaining RMAT approval. Together, these milestones reinforce MeiraGTx’s emergence as a pivotal innovator in advancing both targeted therapies and the broader landscape of genetic medicine.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.